HALIFAX, April 8 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology and solutions, today announced the departure of David Slauenwhite, who served as the Company's Chief Financial Officer. Effective immediately, MedMira is actively conducting a search to hire a new person to fulfill this role.
"The search is underway for a high quality candidate to fill the position of chief financial officer. As MedMira continues to pursue international growth opportunities and engage with strategic partners and customers around the world we are seeking an individual with suitable experience in global finance and accounting, who possesses the ability to add strength and depth to our management team in these areas," said Hermes Chan, Chief Executive Officer, MedMira Inc. "In the meantime, our accounting and operations team members are leading the day-to-day financial activities at MedMira and will ensure an optimal transition."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), Multiplo(TM) and Miriad brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.
For further information: For further information: Andrea Young, Corporate Communications, MedMira, (902) 450-1588, email@example.com